Authors
Latest:
Multidisciplinary Melanoma Program Facilitates Patient Care and Clinical ResearchThe Malignant Melanoma Program at Wake Forest Baptist Health employs a multidisciplinary approach for the management of patients with all stages of this disease. The goals of the program are centered on unequivocal excellence in all areas of care for patients with malignant melanoma.
Latest:
The Jury's Still Out on Whole-Brain Radiation Therapy for Brain MetastasesDespite the fervent advocacy of stereotactic radiosurgery alone, the addition of whole-brain radiation therapy clearly improves local control, decreases distant brain failure, minimizes the need for salvage therapies such as surgery, and, most importantly, decreases neurologic death.
Latest:
Dr. Ward on Multigene Testing in Breast Cancer​​John H. Ward, MD, discusses his preferences in multilane testing for patients with hormone receptor–positive, node-negative breast cancer.
Latest:
Dr. John Haanen on the Role of PD-L1 in Lung CancerJohn Haanen, MD PhD, epartment of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, discussed the role of PD-L1 as a biomarker in lung cancer.
Latest:
Dr. Hays on Targeting Mutations in Gynecologic CancersJohn Hays, MD, assistant professor of Internal Medicine, Ohio State University Comprehensive Cancer Center, discusses how researchers are actively exploring how to target rarer mutations in patients with a variety of gynecologic cancers.
Latest:
Dr Hays on the Evolution of Later-line Treatment Options in Refractory mCRCJohn L. Hays, MD, PhD, discusses the evolution of the treatment paradigm for patients with metastatic colorectal cancer who experience disease progression following standard chemotherapy regimens.
Latest:
Dr Heymach on Updated AEGEAN Data in Resectable NSCLCJohn V. Heymach, MD, PhD, discusses updated outcomes from the AEGEAN trial of perioperative durvalumab vs placebo in resectable non–small cell lung cancer.
Latest:
AEGEAN: A Phase 3 Trial of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable NSCLCExpert oncologist John Heymach, MD, PhD, reviews data from the phase 3 AEGEAN trial following updates presented at the 2023 AACR annual meeting.
Latest:
Dr. Kuruvilla on the Safety of Pembrolizumab in Classical Hodgkin LymphomaJohn Kuruvilla, MD, FRCPC, discusses the safety of pembrolizumab (Keytruda) versus brentuximab vedotin in classical Hodgkin lymphoma.
Latest:
Dr Marshall on Updates in CRC Following the 2024 ASCO Annual MeetingJohn L. Marshall, MD, discuss updates in colorectal cancer management at the 2024 ASCO Annual Meeting.
Latest:
Advanced Cholangiocarcinoma: Molecular TestingExperts who treat patients with GI cancers, such as cholangiocarcinoma, emphasize the need for more standardized approaches to molecular testing.
Latest:
Novel Approaches Under Study for Metastatic CRCJohn L. Marshall, MD; Marwan G. Fakih, MD; and Joleen M. Hubbard, MD, highlight novel strategies in the metastatic colorectal cancer pipeline that look exciting and consider their integration into future clinical practice.
Latest:
Perspectives on Treating CCA Moving ForwardA panel of GI oncologists share their thoughts on the future of using precision medicine to treat patients with bile duct cancers.
Latest:
Dr. Leonard on the Future of PI3K Inhibitors in Follicular LymphomaJohn P. Leonard, MD, discusses the future of PI3K inhibitors in follicular lymphoma.
Latest:
Does Your EHR Consultant Have Your Best Interests in Mind?When selecting an EHR for your practice, using an EHR consultant can save you time, money, and headaches.
Latest:
Dr Burke on Ongoing Investigations in Lymphoma TreatmentJohn M. Burke, MD discussed ongoing investigations into the treatment of lymphoma that were presented at ASCO 2024.
Latest:
Dr Kirkwood on the Evolving Treatment of Resected MelanomaJohn M. Kirkwood, MD, discusses the significance of the FDA approval of adjuvant nivolumab for patients with resected stage IIB or IIC melanoma.
Latest:
Minimal Residual Disease Testing for Patients with Chronic Lymphocytic LeukemiaAdaptive Biotechnologies OncLive Sponsored Content Q&A
Latest:
Delivering Long-Term Results for Blood Cancer PatientsWhile great progress has been made in developing and delivering new treatment options for chronic lymphocytic leukemia, recognizing the chronic nature of the disease and being cognizant of side effects that can have a major impact on a patient’s quality of life remains an important responsibility.
Latest:
Dr. Timmerman on Recent Developments in Hodgkin Lymphoma TreatmentJohn M. Timmerman, MD, discusses recent developments made in the treatment of patients with Hodgkin lymphoma.
Latest:
Future Outlooks in the Treatment of Metastatic Colorectal CancerExperts discuss their vision for the future of colorectal cancer treatment and anticipated advancements in the field.
